Meeting Overview - The annual general meeting of Zhejiang Dayang Biological Technology Group Co., Ltd. was held on May 15, 2025, with both on-site and online voting options available [1][2] - A total of 99 shareholders participated, representing 22,354,962 shares, which is 26.6130% of the total shares [1] Voting Participation - On-site attendance included 23 shareholders, representing 21,442,357 shares, or 25.5266% of total shares [1] - Online voting involved 76 shareholders, representing 912,605 shares, or 1.0864% of total shares [2] - Among the participating small and medium investors, 88 individuals voted, representing 2,602,291 shares, or 3.0980% of total shares [2] Resolutions Passed - The meeting approved the following resolutions: 1. The annual board work report for 2024 was presented and approved [3] 2. The annual supervisory board report for 2024 was presented and approved [3] 3. The 2024 annual report and its summary were approved [3] 4. The estimated daily related transactions for 2025 and confirmation of 2024 transactions were approved, with 111,100 shares opposed, representing 3.4560% of votes [3] 5. The annual financial settlement report for 2024 was approved [4] 6. The financial budget report for 2025 was approved [4] 7. The reappointment of Zhonghui Certified Public Accountants as the auditing firm for 2025 was approved, with an audit fee of 800,000 yuan [4] 8. The profit distribution plan for 2024 was approved, proposing a cash dividend of 3.00 yuan per 10 shares, with 994,070 shares excluded from the total [5] 9. The confirmation of the remuneration for directors and supervisors for 2024 was approved [6] 10. The remuneration scheme for directors and supervisors was approved [6] 11. The financing and guarantee proposal for the company and its subsidiaries was approved, allowing for bank financing up to 600 million yuan and guarantees up to 300 million yuan [7] Legal Opinion - The legal opinion provided by Shanghai Jintiancheng Law Firm confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations [7]

上海市锦天城律师事务所 关于浙江大洋生物科技集团股份有限公司 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江大洋生物科技集团股份有限公司 法律意见书 致：浙江大洋生物科技集团股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江大洋生物科技集团股 份有限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东会规则》等法律、法规、规章和其他规范性文 （以下简称"《公司章程》"） 件以及《浙江大洋生物科技集团股份有限公司章程》 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核 ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-044 浙江大洋生物科技集团股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间不存在增加、否决或变更提案的情形。 2、本次股东大会采取现场投票表决和网络投票表决相结合的方式进行。 一、会议召开和出席情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议主持人：公司董事长陈阳贵先生 4、会议召开的合法、合规性：本次股东大会会议的召集、召开程序符合《中 华人民共和国公司法》《上市公司股东大会规则》和《浙江大洋生物科技集团股 份有限公司章程》的有关规定。 5、会议召开日期和时间 （1）现场会议时间：2025 年 5 月 15 日下午 2:00 （2）网络投票时间：2025 年 5 月 15 日（星期四）其中：通过深圳证券交 易所交易系统进行网络投票的具体时间为 2025 年 5 月 15 日（星期四） 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交 ...

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 关于浙江大洋生物科技集团股份有限公司 2024 年年度股东大会的 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江大洋生物科技集团股份有限公司 2024 年年度股东大会的 法律意见书 致：浙江大洋生物科技集团股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江大洋生物科技集团股 份有限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下 简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东会规则》等法律、法规、规章和其他规范性文 件以及《浙江大洋生物科技集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本 ...

Group 1 - Company announced an earnings briefing on May 13, 2025 [1] - Company is actively applying and exploring the expansion of artificial intelligence in its operations [2] - The company is in the construction phase of the trifluoroacetyl series product project, which is an important raw material in the organic chemical field [6][29] Group 2 - The company aims to strengthen its potassium salt position, expand the fluorine industry, increase veterinary drug varieties, and enhance R&D capabilities as part of its development strategy [9] - The company is currently focusing on the semiconductor materials sector through its investment in Chip Pure Semiconductor [17] - The company reported a significant increase in sales revenue for Q1 2025, with a year-on-year growth of 27.78% [40] Group 3 - The company is considering mergers and acquisitions as part of its strategic planning [7][8] - The company is committed to improving its market valuation and investor returns despite current low market capitalization [13][26][39] - The company is monitoring the impact of new U.S. tariff policies, noting that its export sales to the U.S. are relatively small and have not had a significant negative impact [38]

Group 1: Company Performance and Market Position - The company reported a significant increase in sales revenue in Q1 2025 compared to the same period last year, with stable order levels [7] - The design capacity for the trifluoroacetyl series project is set at 3,800 tons per year, currently under construction [10] - The company is recognized as a leading player in its industry, yet its market capitalization remains low due to various factors [9][15] Group 2: Strategic Initiatives and Future Plans - The company is actively exploring the application of artificial intelligence across various sectors [2] - Future development strategies include consolidating potassium salt positions, expanding fluorine chemical products, and enhancing veterinary drug varieties [3] - The semiconductor investment in Zhejiang Chip Pure is a strategic move to enter the semiconductor materials sector, with products expected to be launched by the end of 2025 [6][8] Group 3: Investor Relations and Market Communication - The company emphasizes the importance of maintaining communication with institutional investors to reflect its equity value [3] - There is a commitment to improving market value management and investor returns, despite the challenges faced [9][15] - The company plans to consider multiple profit distributions within a year, subject to regulatory encouragement [12][14]

暨 2024 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，提升公司投资者关系管理水平，浙江大 洋生物科技集团股份有限公司（以下简称"公司"）将参加由浙江证监局指导， 浙江上市公司协会主办，深圳市全景网络有限公司承办的"2025 年浙江辖区上 市公司投资者集体接待日暨 2024 年度业绩说明会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2025 年 5 月 13 日（周二）15:00-17:00。届时， 公司董事长陈阳贵先生，董事、总经理兼财务总监陈旭君女士，董事会秘书徐旭 平先生，独立董事姜晏先生（如遇特殊情况，参与人员会有调整）将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者 进行沟通和交流，欢迎广大投资者踊跃参与。 特此公告。 浙江大洋生物科技集团股份有限公司董事会 2025 年 5 月 ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-042 浙江大洋生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司""本公司"或"大 洋生物"）于 2024 年 10 月 17 日召开第五届董事会第二十次会议、第五届监事会 第十四次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的议 案》。根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范 运作》等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影响 募投项目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以下 简称"福建舜跃"）使用最高额度不超过 14,000.00 万元（含本数）闲置募集资金 进行现金管理（在此额度内可滚动使用），自董事会审议通过之日起 12 个月之内 有效。具体内容详见公司在《证券时报》《证券日报》《中国证券报》和巨潮资 讯网（http://www.cninfo.com.cn）上 ...

Market Overview - The total trading volume of the Shanghai and Shenzhen stock markets exceeded 500 billion yuan, indicating strong market activity [1] - The A-share market opened slightly lower, with the Shanghai Composite Index down 0.07% and the Shenzhen Component Index up 0.03% [1] Sector Performance - The robotics sector showed significant strength, with related stocks experiencing sharp increases and some hitting the daily limit [6][12] - The chemical and chemical engineering sector also saw continuous gains, particularly in the PEEK materials segment, which performed strongly [14][15] - Electric power stocks faced a collective downturn, with several stocks hitting the daily limit down, including Shaoneng Co., Leshan Electric Power, and others [18] Notable Stocks - Stocks such as Aotuo Electronics, Yinbao Xingshan, and Tianqi Co. rapidly surged to their daily limit [12] - PEEK materials index rose by 8.73%, with a trading volume of 7.08 billion yuan, indicating strong investor interest [15] - Specific stocks like Fuheng New Materials and Jusa Long saw increases of over 20% [17] Investment Insights - According to Guojin Securities, the humanoid robot sector is entering a mass production phase, which is expected to benefit upstream core chemical new materials, including high-end engineering plastics like PEEK and others [17]

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in its announcements [7][22]. - The board of directors and senior management confirm the truthfulness of the quarterly report and assume legal responsibility for any misrepresentation [2][3]. - The first quarter report for 2025 has not been audited [6]. Group 2 - The profit distribution plan for 2024 proposes a cash dividend of 3.00 yuan per 10 shares, totaling approximately 24.90 million yuan, which is 39.06% of the net profit attributable to shareholders [9][10]. - The total distributable profit for 2024 is 34.85 million yuan, after accounting for legal reserves and previous undistributed profits [9][10]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [12][13]. Group 3 - The company plans to engage in financial derivatives trading in 2025 to hedge against currency and interest rate risks, with a maximum contract value of 250 million yuan [23][25]. - The board has approved the financial derivatives trading proposal, which aims to use self-owned funds for hedging purposes [26]. - The company will implement risk control measures to mitigate potential market, liquidity, and legal risks associated with financial derivatives trading [27][28]. Group 4 - The company has outlined expected related party transactions for 2025, including procurement and service agreements, with total amounts not exceeding 30 million yuan [32][38]. - The related party transactions are conducted at market prices and are not expected to significantly impact the company's financial status or independence [38][41]. - The independent directors have reviewed and approved the related party transactions before submission to the board [39].